Table 1. MARV vaccines with protective efficacy in the preclinical NHP model.

Vaccine	Challenge Virus	Vaccine doses	Time between doses [d]	Time to Challenge [d]*	Survival [%]	Developer	Ref.
Whole Virus
inact. MARV	MARV Popp	2	14	21	50		[18]
Subunit
VLPs + adjuvant	MARV Musoke	3	42	28	100		[18]
VLPs + adjuvant	MARV Musoke, Angola	3	42	28	100	USAMRIID	[18]
MARV GP + adjuvant	MARV Angola	3	21	28	100		[39]
MARV GP, EBOV GP + adjuvant	MARV Angola	3	21	28	100		[39]
DNA
MARV GP	MARV Musoke	3	28	28	67	USAMRIID	[18]
MARV GP	MARV Angola	4	3× 28, then 105	21	100	NIAID	[18]
MARV GP, RAVV GP, EBOV GP, SUDV GP	MARV Musoke	3	28	56	100	USAMRIID	[18]
DNA + rec. Adenovirus
3x DNA-MARV GP, 1x rAd5-MARV GP	MARV Angola	4	28 DNA, then 84 rAd5	42	100	NIAID	[18]
Replicon
VEEV-MARV GP, VEEV-MARV NP, both	MARV Musoke	3	28	35	67–100	USAMRIID	[18]
rec. Adenovirus
CAdVax-panFilo	MARV Musoke, Ci67	2	63	42 or 112	100		[18]
rAd5-MARV GP	MARV Angola	1	n/a	28	100		[18]
rAd26-MARV GP + rAd35-MARVGP	MARV Angola	2	28	28	100	Janssen	[19]
ChAd3-MARV	MARV Angola	1	n/a	7, 14, 21, 28, 35, or 185	100	Sabin	[21]
ChAd3-MARV	MARV Angola	1	n/a	365	75	Sabin	[21]
rec. Vesicular stomatitis virus
VSV-MARV	MARV Musoke, Popp	1	n/a	28 or 113	100	PHAC, IAVI	[18]
VSV-MARV	MARV Musoke, Angola, RAVV	1	n/a	28	100	PHAC, IAVI	[18]
VSV-MARV	MARV Angola	1	n/a	28	100	PHAC, IAVI	[18]
VSV-EBOV, VSV-SUDV, VSV-MARV	MARV Musoke	1	n/a	28 or 59	100	PHAC, IAVI	[18]
VSV-MARV	MARV Musoke	1	n/a	407	100	PHAC, IAVI	[18]
VSV-MARV	MARV Angola	1	n/a	35	100	PHAC, PHV	[27]
VSV-MARV	MARV Angola	1	n/a	14 or 7	100	PHAC, PHV	[28]
VSV-MARV	MARV Angola	1	n/a	3	75	PHAC, PHV	[28]
VSV-N4CT1-MARV	MARV Angola	1	n/a	7	100	Auro Vaccines	[25]
VSV-N4CT1-MARV	MARV Angola	1	n/a	5	80	Auro Vaccines	[25]
VSV-N4CT1-MARV	MARV Angola	1	n/a	3	20	Auro Vaccines	[25]
Trivalent VesiculoVax	MARV Angola	1	n/a	28	100	Auro Vaccines	[24]
Quadrivalent VesiculoVax	MARV Angola	2	56	28	100	Auro Vaccines	[23]

*Time until challenge after vaccination was completed.

n/a, not applicable.